ClinicalTrials.gg
Not yet recruitingNCT07722169VRTADUpdated Aug 3, 2026

Telerehabilitation in Alzheimer's Disease

An interventional study of Online cognitive telerehabilitation and VRRS tablet in Alzheimer, sponsored by IRCCS San Raffaele. Not yet recruiting. Open to participants aged 50 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by IRCCS San Raffaele · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Alzheimer Disease by IRCCS San Raffaele — 8 open to participants now, 8 under way, none of them phase 3. Alzheimer Disease · IRCCS San Raffaele.

Started
2026
with 3 others
No phase
4 of 10
4 open now
Registered
8th of 10
by date

Among the 10 studies in Alzheimer Disease by IRCCS San Raffaele, this one is one of 4 that started in 2026, is one of 4 with no phase, and was the 8th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 10 studies in Alzheimer Disease by IRCCS San Raffaele are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alzheimer Disease by IRCCS San Raffaele, or all of them as a file.
02

Study summary

Telemedicine has developed rapidly during the COVID-19 pandemic and is now integrated into the clinical practice of many hospitals. Telemedicine offers many advantages, and even after the end of the pandemic, many patients still choose to undergo healthcare visits remotely. However, the rapid expansion of telemedicine may be associated with the risk of providing patients with unvalidated and uncontrolled telehealth solutions, potentially negatively impacting their health.

In this study, the researchers aim to investigate the effectiveness of remote cognitive training in patients with mild-to-moderate Alzheimer's disease (AD) using tablets equipped with virtual reality-based cognitive exercises. The investigators also aim to evaluate the impact of online supervision of cognitive training by a neuropsychologist and to compare the costs and burden of home-based versus hospital-based cognitive training in patients with AD. This project will define the optimal modalities for cognitive telerehabilitation to ensure validated protocols for the continuity of care in AD.

Read the detailed description

This project aims to use new technologies and telemedicine to ensure continuity of care and slow cognitive decline in patients with Alzheimer's disease (AD). The investigators also aim to reduce caregiver burden and healthcare costs for the national healthcare system.

The investigators hypothesize that patients provided with a VRRS tablet and undergoing autonomous cognitive training as an adjunct to cognitive telerehabilitation will achieve better cognitive outcomes than patients who do not receive a VRRS tablet.

The investigators also hypothesize that patients receiving both forms of cognitive training-autonomous training using the VRRS tablet combined with online cognitive telerehabilitation supervised by a professional neuropsychologist-will show greater improvements in cognitive function than patients who do not receive online cognitive telerehabilitation.

This is a prospective, interventional, randomized, single-blind, monocentric clinical study.

Study population: 48 patients with AD (MMSE score 18-24) and one caregiver for each patient (48 caregivers in total).

To minimize potential bias, the neuropsychologist responsible for patient and caregiver assessments will be blinded to treatment allocation.

Patients will be randomized in a 1:1:1 ratio to one of the following treatment groups:

  • Intervention Group 1:** 16 patients provided with a VRRS tablet to perform autonomous home-based cognitive training (5 days per week), in addition to online cognitive telerehabilitation sessions supervised by a neuropsychologist at San Raffaele Hospital twice weekly.
  • Intervention Group 2:** 16 patients provided with a VRRS tablet to perform autonomous home-based cognitive training (5 days per week), without neuropsychologist-supervised cognitive telerehabilitation.
  • Comparator Group 3:** 16 patients receiving online cognitive telerehabilitation sessions supervised by a neuropsychologist twice weekly. These patients will not receive a VRRS tablet for home use.

No interim analysis is planned.

Study design:

Each group will undergo a 3-month intervention according to the following schedule.

Group 1:

Autonomous home-based cognitive training using the VRRS tablet for 1 hour per day, 5 days per week.

Remote cognitive telerehabilitation sessions supervised by a neuropsychologist twice weekly.

Group 2:

Autonomous home-based cognitive training using the VRRS tablet for 1 hour per day, 5 days per week.

No cognitive telerehabilitation sessions.

Group 3:

Remote cognitive telerehabilitation sessions supervised by a neuropsychologist twice weekly.

No VRRS tablet and no additional autonomous home-based cognitive training.

- Study visits:

Patients and caregivers will attend the following visits:

  1. Enrolment.
  2. Screening (Day 1) and treatment initiation.
  3. Post-treatment assessment (after 3 months of treatment).
  4. Follow-up assessment (3 months after completion of treatment).

    • Methods of data collection

The following data will be collected:

  • patients' neuropsychological performance;
  • electroencephalographic (EEG) activity;
  • caregivers' mental health and caregiver burden;
  • system usability;
  • costs associated with telerehabilitation and cognitive training.
  • Assessment of patients' neuropsychological performance:

Patients will undergo a comprehensive neuropsychological assessment at three time points: baseline, after the 3-month treatment period, and at the 3-month follow-up.

The assessment battery will include:

  • Montreal Cognitive Assessment (MoCA) (primary outcome): a screening tool for cognitive impairment providing a total score and six domain-specific index scores (Memory, Executive Function, Attention, Language, Visuospatial Ability, and Orientation). Total scores range from 0 to 30, with scores ≥26 generally considered normal.
  • Mini-Mental State Examination (MMSE).
  • Quality of Life in Alzheimer's Disease (QoL-AD).
  • Geriatric Depression Scale (GDS).
  • Attention Matrices.
  • Raven's Progressive Matrices.
  • Token Test.
  • Semantic Fluency Test.
  • Phonemic Fluency Test.
  • Naming Test.
  • Word-Picture Naming Test.
  • Digit Span Test (forward and backward).
  • Corsi Block-Tapping Test.
  • Rey Complex Figure Test.
  • Trail Making Test.
  • EEG assessment:

Five minutes of resting-state EEG will be recorded using 32-channel EEG caps before and after the intervention to perform time-frequency analyses.

  • Assessment of caregivers' mental health and burden:
  • Beck Depression Inventory-II (BDI-II).
  • Zarit Burden Interview.

Assessment of system usability:

System Usability Scale (SUS). Usability will be evaluated in terms of effectiveness, efficiency, and user satisfaction.

- Assessment of the costs of telerehabilitation and cognitive training:

The following cost components will be analysed:

  • healthcare professional costs (neuropsychologist);
  • outpatient clinic costs;
  • telemedicine equipment costs for both patients and the hospital;
  • patients' travel costs;
  • cognitive training equipment costs;
  • caregiver burden;
  • system usability.

Any future research involving the collected data will require prior approval from the Ethics Committee (EC).

03

Conditions studied

  • Alzheimer

Browse trials for

Keywords

  • cognitive training
  • telerehabilitation
  • virtual reality
  • Alzheimer's disease
  • Cognitive functions
  • caregiver
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria for patients with Alzheimer's disease (AD):

  • Age between 50 and 90 years.
  • Diagnosis of Alzheimer's disease according to established diagnostic criteria.
  • (MMSE) score between 18 and 24.
  • Stable pharmacological treatment for at least 3 months before enrolment.
  • Ability and willingness to provide written .

Inclusion criteria

Inclusion criteria for caregivers:

  • Age ≥18 years.
  • Availability to assist the patient throughout the study.
  • Ability and willingness to provide written informed consent.

Exclusion criteria for patients with Alzheimer's disease (AD):

  • Refusal or inability to provide written informed consent.
  • History of psychiatric disorders.
  • Significant cerebrovascular disease.
  • Severe visual or hearing impairment that could interfere with study procedures.
  • Psychosis.
  • Major depressive disorder.
  • Alcohol or substance abuse.
  • Use of psychotropic medications that may interfere with neuropsychological assessment or study treatment.
  • Concurrent participation in another interventional pharmacological clinical trial.
  • Any to undergoing EEG recording.

Exclusion criteria

Exclusion criteria for caregivers:

  • Refusal or inability to provide written .
  • History of psychiatric disorders.
  • Major depressive disorder.
  • Alcohol or substance abuse.
  • Use of psychotropic medications that may interfere with neuropsychological assessment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Tablet + Telerehabilitation

    Group 1: Participants will perform autonomous home-based cognitive training using a VRRS tablet (Khymeia Home Tablet) for 5 days per week, combined with online cognitive telerehabilitation sessions conducted twice weekly by a neuropsychologist based at San Raffaele Hospital (telemedicine sessions delivered remotely between the patient's home and the hospital). The intervention will last 3 months.

    Device: Online cognitive telerehabilitation · Device: VRRS tablet

  • Experimental
    Tablet only

    Group 2: Participants will perform autonomous home-based cognitive training using a VRRS tablet (Khymeia Home Tablet) for 5 days per week. No cognitive telerehabilitation sessions supervised by a neuropsychologist will be provided. The intervention will last 3 months.

    Device: VRRS tablet

  • Active comparator
    Telerehabilitation only

    Group 3: Participants will receive online cognitive telerehabilitation sessions supervised by a neuropsychologist twice weekly (telemedicine sessions delivered remotely between the patient's home and the hospital). Participants will not receive a VRRS tablet and will not perform additional autonomous home-based cognitive training.

    Device: Online cognitive telerehabilitation

Interventions

  • DeviceOnline cognitive telerehabilitation

    Online sessions of cognitive telerehabilitation, twice a week, supervised by a neuropsychologist based at the San Raffaele hospital.

  • DeviceVRRS tablet

    Patients equipped with VRRS tablets to undergo autonomous home-based cognitive training (5 days a week).

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment (MoCA)

    MoCA is a screening instrument to detect cognitive impairment. It generates a total score and six domain-specific index scores: (1) Memory, (2) Executive Functioning, (3) Attention, (4) Language, (5) Visuospatial, and (6) Orientation. The total possible score is 30 points; a score of 26 or above is considered normal, while scores below 26 may indicate cognitive impairment. Increase in MoCA scores meaning improvement in cognitive functioning.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

Secondary outcomes

  1. Electroencephalographic (EEG) activity

    Patients' electroencephalographic activity: 5 min of resting state EEG will be recorded using a 32 channel cap in order to perform time-frequency analyses before and after training. EEG power in the alpha, beta and theta rangers will be analyzed.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  2. Caregivers' mental status

    \- Beck Depression Inventory-II (BDI): 21-item self-report instrument assessing the common cognitive symptoms of depression. BDI is considered a valid and reliable instrument for depression screening in the general population. The BDI is scored by summing the highest ratings for each of the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3, and the total scores can range from 0 to 63. BDI total scores ranging from 0 to 13 represent "Minimal" depression; total scores from 14 to 19 represent "Mild" depression; total scores from 20 to 28 represent "Moderate" depression; and total scores from 29 to 63 represent "Severe" depression.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  3. Caregivers' burden

    Zarit Burden Interview: a standardized, 22-item assessment tool used by healthcare professionals to measure the subjective burden experienced by caregivers of individuals with chronic illnesses or dementia. It evaluates the emotional, physical, social, and financial impacts of caregiving to identify individuals at risk for burnout. It contains 22 questions rated on a 5-point scale (0 = Never, 1 = Rarely, 2 = Sometimes, 3 = Quite frequently, 4 = Nearly always). The total score ranges from 0 to 88, with higher scores indicating greater perceived strain.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  4. System usability

    System Usability Scale (SUS): a reliable, 10-item questionnaire used in research to quickly measure the perceived usability of a product, software, or website. Usability measurements consider different aspects: effectiveness (users can successfully achieve their goals), efficiency (how much effort and resources are spent to achieve those goals) and satisfaction (the experience was satisfactory). Participants rate 10 statements (alternating positive and negative) on a 5-point scale (1 = Strongly Disagree, 5 = Strongly Agree), covering areas like ease of use, consistency, and complexity. A SUS score does not represent a percentage. Instead, scores are generally understood using standardized benchmarks and grading scales: (1) 80.3: Excellent (Grade A); (2) 71 - 80: Good (Grade B); (3) 68: Okay/Average; (4) 51 - 68: Poor (Grade C/D); (5) \<51: Worst Imaginable (Grade F).

    Time frame: At the end of the 3-month rehabilitation period.

  5. Telerehabilitation's costs

    The total costs for 3 months of telerehabilitation will be evaluated. Costs related to the following elements will be summed up: * pay for a neuropsychologist twice a week, for 3 months; * telemedicine equipment costs for patients (tablet, internet) * telemedicine equipment costs for the hospital (computer, internet, room).

    Time frame: At 3 months follow-up.

  6. Mini Mental State Examination (MMSE)

    The MMSE is a 30-point, 11-question screening tool used by clinicians to assess cognitive impairment. It evaluates functions like memory, orientation, attention, language, and visuospatial skills, taking just 5 to 10 minutes to administer. It is most commonly used to detect conditions like dementia or track cognitive decline over time. The MMSE covers several key domains of mental ability to establish a comprehensive overview of a person's present cognitive performance: Orientation (10 points), registration (3 points), Attention and Calculation (5 points), Recall (3 points), Language and Visual Construction (9 points). Scores are tallied out of 30, with higher scores indicating better cognitive function. A score of 24 or higher is generally considered normal, while scores below that threshold suggest varying levels of cognitive impairment.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  7. Quality of Live in Alzheimer's Disease (QoL-AD)

    The QOL-AD is a 13-item questionnaire designed to assess-through both the patient and the caregiver-the quality of life (QOL) of patients diagnosed with Alzheimer's disease (AD). The scale comprises 13 items measuring physical condition, mood, memory, functional abilities, interpersonal relationships, the ability to participate in meaningful activities, financial situation, and global assessments of self and overall QOL. Items are rated on a four-point scale, with descriptors ranging from 1 (poor) to 4 (excellent). Separate scores are calculated for patients and caregivers and then combined into a composite score (QoL-AD CS), in which patient ratings are weighted twice as heavily as caregiver ratings.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  8. Geriatric Depression Scale (GDS)

    The most widely used rating scale for assessing depressive symptoms in frail elderly patients and patients with dementia. The scale consists of 15 binary-response questions (yes or no), each scored as 1 or 0. The final score ranges from 0 (no depressive symptoms) to 15 (probable presence of depression).

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  9. Attention matrices

    Attentional Matrices is a classic paper-and-pencil diagnostic tool primarily used to assess selective visual attention and visual scanning. It requires patients to rapidly identify and cross out target numbers hidden among distractors within a strict time limit. The test typically consists of three separate matrices containing rows and columns of random digits. The patient is handed a sheet and given a brief timeframe (usually 45 seconds) to scan the matrix and cross out specific, pre-defined target numbers. The task becomes progressively complex across the three matrices.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  10. Raven's Progressive Matrices (RPM)

    RPM are a widely used, non-verbal psychometric assessment designed to measure fluid intelligence, abstract reasoning, and problem-solving skills. It evaluates an individual's ability to deduce relationships, identify patterns, and impose meaning on complex, abstract visual information. Test-takers are presented with a series of visual matrices-typically 3 × 3 geometric patterns-with one piece missing. The goal is to identify the underlying logical rule governing the pattern and select the correct missing piece from a set of multiple-choice options. The test is "progressive" because the visual puzzles begin simply and become increasingly difficult, demanding more complex cognitive operations to solve as the test goes on.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  11. Token test

    The Token Test is a standardized neuropsychological assessment used to evaluate receptive language disorders (auditory comprehension). It requires patients to follow increasingly complex spoken commands to manipulate small, colored plastic shapes (tokens). During the assessment, 20 physical tokens-featuring combinations of two shapes (circles and squares), two sizes (large and small), and five colors (red, blue, green, yellow, and white)-are placed in front of the patient. The test is typically divided into six sections of increasing difficulty: Simple commands: "Touch the red circle"; Complex/Two-part commands: "Touch the large green square and the small red circle"; Relational commands: "Touch the red circle with the blue sqaure". While the original test by A widely used short version consists of 36 commands. Points are awarded for correct manipulations. Lower or cutoff scores (e.g., 25 or below on the 36-item version) indicate varying levels of receptive language impairments.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  12. Semantic and phonemic fluency

    emantic and phonemic fluency are critical neuropsychological tests evaluating language and executive functions like working memory, mental flexibility, and strategy generation. Semantic fluency requires producing words within a specific category (e.g., animals), heavily relying on temporal lobe networks and semantic memory. Phonemic fluency requires generating words starting with a specific letter (e.g., F, A, S), taxing frontal lobe executive systems and phonological knowledge. The primary score is the sum of all valid, unique words generated within the 60-second limit.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  13. Naming

    Naming test evaluates an individual's ability to retrieve and articulate the names of visually presented objects or pictures. It is primarily used to diagnose anomia (word-finding difficulty) and localize language impairments caused by stroke, traumatic brain injury, or neurodegenerative diseases like Alzheimer's.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  14. Word-picture naming test

    It is a core neuropsychological evaluation that asks a patient to verbally identify common objects, animals, or actions shown in pictures. It is used to measure lexical retrieval (word finding), semantic memory, and speech fluency. The examiner presents a series of line drawings or photographs one by one. The patient is asked to state the name of the object as quickly and accurately as possible.

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  15. Digit Span test

    The Digit Span test is a core neuropsychological assessment of memory. It features two parts: Digits Forward, which measures passive short-term verbal memory and attention by requiring verbatim repetition, and Digits Backward, which assesses executive working memory by demanding mental manipulation and sequence reversal. Digits Forward: The examiner reads a random sequence of numbers aloud (e.g., "5-8-2-1") at a rate of one digit per second. The participant must repeat the sequence in the exact same order. Digits Backward: The examiner reads a sequence of numbers, and the participant must repeat the sequence in reverse order (e.g., if the examiner says "3-9-2", the correct response is "2-9-3").

    Time frame: (1) before telerehabilitation, (2) at the end of the 3-month rehabilitation period, and (3) 3 months following the end of treatment.

  16. Hospital-based cognitive training costs

    The total costs for 3 months of cognitive rehabilitation in the outpatient clinic of the San Raffaele Hospital (Milan, Italy) will be evaluated. Costs related to the following elements will be summed up: * pay for a neuropsychologist twice a week, for 3 months; * cognitive training equipment costs for the hospital (computer, rehabilitation material, outpatient room). * costs related to patients' travel to and from the hospital.

    Time frame: At 3 months follow-up.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gatica-Rojas V, Mendez-Rebolledo G. Virtual reality interface devices in the reorganization of neural networks in the brain of patients with neurological diseases. Neural Regen Res. 2014 Apr 15;9(8):888-96. doi: 10.4103/1673-5374.131612. PubMed 25206907 ↗
  • Yang JG, Thapa N, Park HJ, Bae S, Park KW, Park JH, Park H. Virtual Reality and Exercise Training Enhance Brain, Cognitive, and Physical Health in Older Adults with Mild Cognitive Impairment. Int J Environ Res Public Health. 2022 Oct 15;19(20):13300. doi: 10.3390/ijerph192013300. PubMed 36293881 ↗
  • Laver KE, George S, Thomas S, Deutsch JE, Crotty M. Virtual reality for stroke rehabilitation. Cochrane Database Syst Rev. 2015 Feb 12;2015(2):CD008349. doi: 10.1002/14651858.CD008349.pub3. PubMed 25927099 ↗
  • Buschert V, Bokde AL, Hampel H. Cognitive intervention in Alzheimer disease. Nat Rev Neurol. 2010 Sep;6(9):508-17. doi: 10.1038/nrneurol.2010.113. Epub 2010 Aug 17. PubMed 20717104 ↗
  • Emedoli D, Houdayer E, Della Rosa PA, Zito A, Brugliera L, Cimino P, Padul JD, Tettamanti A, Iannaccone S, Alemanno F. Continuity of care for patients with dementia during COVID-19 pandemic: flexibility and integration between in-person and remote visits. Front Public Health. 2024 Jan 8;11:1301949. doi: 10.3389/fpubh.2023.1301949. eCollection 2023. PubMed 38259745 ↗
  • Emedoli D, Alemanno F, Houdayer E, Brugliera L, Iannaccone S, Tettamanti A. Mobile application tool for remote rehabilitation after discharge from coronavirus disease-19 rehabilitation unit. Healthc Technol Lett. 2022 Aug 8;9(4-5):70-76. doi: 10.1049/htl2.12033. eCollection 2022 Aug-Oct. PubMed 36225346 ↗
  • Elbaz S, Cinalioglu K, Sekhon K, Gruber J, Rigas C, Bodenstein K, Naghi K, Lavin P, Greenway KT, Vahia I, Rej S, Sekhon H. A Systematic Review of Telemedicine for Older Adults With Dementia During COVID-19: An Alternative to In-person Health Services? Front Neurol. 2021 Dec 14;12:761965. doi: 10.3389/fneur.2021.761965. eCollection 2021. PubMed 34970210 ↗
  • Grabher BJ. Effects of Alzheimer Disease on Patients and Their Family. J Nucl Med Technol. 2018 Dec;46(4):335-340. doi: 10.2967/jnmt.118.218057. Epub 2018 Aug 23. PubMed 30139888 ↗
  • Manenti R, Gobbi E, Baglio F, Macis A, Ferrari C, Pagnoni I, Rossetto F, Di Tella S, Alemanno F, Cimino V, Binetti G, Iannaccone S, Bramanti P, Cappa SF, Cotelli M. Effectiveness of an Innovative Cognitive Treatment and Telerehabilitation on Subjects With Mild Cognitive Impairment: A Multicenter, Randomized, Active-Controlled Study. Front Aging Neurosci. 2020 Nov 16;12:585988. doi: 10.3389/fnagi.2020.585988. eCollection 2020. PubMed 33304267 ↗

Individual participant data

Plan to share: No — We do not plan to share IPD since this is a monocentric study, but all outcomes will be recorded and stored on a eCRF platform and will be be able to share data if requested by other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2029, 36 months later.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 36 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Jul 23, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07722169
Lead sponsor
IRCCS San Raffaele
Responsible party
Sandro Iannaccone (Director of Neurorehabilitation and Functional Recovery Department, IRCCS San Raffaele) — Principal investigator
First posted
Jul 23, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Aug 3, 2026

Study contacts

Elise Houdayer, PhD
Contact
houdayer.elise@hsr.it
+390226435739
Sandro Iannaccone, MD
Contact
iannaccone.sandro@hsr.it
+390226435760

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion